Want to see AU:IMR full AI Analyst Report?
IMR Stock Chart & Stats
AU$1.92
AU$0.08(4.17%)
At close: 4:00 PM EDT
AU$1.92
AU$0.08(4.17%)
Day’s Range― - ―
52-Week RangeAU$1.28 - AU$2.25
Previous CloseN/A
Volume934.18K
Average Volume (3M)1.01M
Market Cap
AU$559.37M
Enterprise ValueAU$579.50
Total Cash (Recent Filing)AU$67.46M
Total Debt (Recent Filing)AU$34.02M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Feb 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding358,650,630
10 Day Avg. Volume1,870,797
30 Day Avg. Volume1,014,156
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)27.34
Price to Sales (P/S)1042.05
P/FCF Ratio-15.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.98Price Target Upside55.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.09
Revenue Forecast (FY)AU$2.30M
Bulls Say, Bears Say
Bulls Say
MRI-guided Device SpecializationImricor operates in a specialized medical-device niche focused on MRI-compatible electrophysiology. This differentiated product focus could support durable adoption if hospitals expand MR-guided cardiac procedures, while technical specialization may strengthen its position within that workflow.
Procedure-linked Revenue ModelThe business model links revenue to clinical utilization because catheters and related consumables are used during procedures. If installed sites increase procedure volumes, recurring per-procedure sales could provide operating leverage and make growth more scalable over time.
Equity Balance-sheet ImprovementThe return to positive equity is a meaningful improvement from the prior two years and reduces immediate balance-sheet stress relative to that period. It provides a stronger capital base for ongoing commercialization, although the benefit remains limited while losses and debt stay high.
Bears Say
Severe Revenue And Profitability WeaknessVery small and declining revenue, negative gross profit, and a large net loss indicate that the company has not yet achieved commercial scale or operating leverage. This weak earnings base may continue to constrain investment capacity and make sustainable profitability dependent on substantial growth.
Persistent Cash ConsumptionPersistent operating and free-cash-flow deficits show that the business is not yet self-funding. Continued cash consumption can require additional financing while commercialization progresses, potentially limiting strategic flexibility and increasing the consequences of slower-than-expected procedure adoption.
Elevated Leverage And Funding RiskDebt materially exceeds the company’s positive equity base while losses continue, creating a fragile funding structure. Refinancing needs or further capital raising could absorb future resources, and the pack specifically identifies increased refinancing and dilution risk if losses persist.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh News
IMR FAQ
What was Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price range in the past 12 months?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh lowest share price was AU$1.27 and its highest was AU$2.25 in the past 12 months.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s market cap is AU$559.37M.
When is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s upcoming earnings report date is Feb 24, 2027 which is in 144 days.
How were Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s earnings last quarter?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh released its earnings results on Aug 09, 2026. The company reported -AU$0.028 earnings per share for the quarter, beating the consensus estimate of -AU$0.045 by AU$0.017.
Is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh overvalued?
According to Wall Street analysts Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price is currently Undervalued.
Does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pay dividends?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh does not currently pay dividends.
What is Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh have?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 358,650,630 shares outstanding.
What happened to Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s price movement after its last earnings report?
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh reported an EPS of -AU$0.028 in its last earnings report, beating expectations of -AU$0.045. Following the earnings report the stock price went up 1.508%.
Which hedge fund is a major shareholder of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh?
Currently, no hedge funds are holding shares in AU:IMR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Imricor Medical Systems, Inc., a medical device company, designs, manufactures, sells, and distributes magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures in the United States, Europe, and the Middle East. The company’s products include Vision-MR Ablation Catheter 2.0, a MR-compatible cardiac ablation catheter; Vision-MR Diagnostic Catheter, a MR-compatible diagnostic catheter; NorthStar mapping system, a real-time, high-resolution soft tissue imaging of MRI to guide and visualize procedures with exceptional clarity; and Advantage-MR EP Recorder / Stimulator. It also offers Vision-MR Dispersive Electrode to minimize eddy currents induced on the device’s conductive pads during mr scanning. Imricor Medical Systems, Inc. was incorporated in 2006 and is headquartered in Burnsville, Minnesota.
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (IMR) Earnings & Revenues
IMR Stock 12 Month Forecast
Average Price Target
AU$2.98
▲(55.34% Upside)
Technical Analysis
Impedimed Limited
―
HeraMED Ltd.
―
Cyclopharm Limited
―
Micro-X Ltd.
―
EMvision Medical Devices Ltd.
―





